Thus, tumors in the later injected CreERT2-p53F/F cohorts exhibit a reduction in median and maximum tumor-free post-injection survival, suggesting that these mice have an increased accumulation of pre-neoplastic or neoplastic clones that require loss of p53 to allow full tumor progression. Here, TP53 is linked to neoplasm.